Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B4
Source: 0001062993-25-010548
Chunk: 14

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B4
Chunk 14
---
7

SELECTED HISTORICAL CONSOLIDATED FINANCIAL INFORMATION</div>

The following tables set forth our selected historical consolidated financial information. You should read the selected historical consolidated financial information in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and related notes included elsewhere in this prospectus.

We have derived the selected consolidated statement of operations for the three months ended March 31, 2025 and 2024 and the selected consolidated balance sheet information as of March 31, 2025 and December 31, 2024 from our interim unaudited consolidated financial statements and audited consolidated financial statements, respectively, included elsewhere in this prospectus. Our consolidated financial statements have been prepared in accordance with GAAP and our consolidated financial statements are presented in U.S. dollars, except where indicated otherwise. Our historical results are not necessarily indicative of the results that should be expected in any future period.

<div align='center'>CONSOLIDATED STATEMENT OF OPERATIONS</div>

| Operating expenses                                                         |   | Three Months  Ended March 31, 
                          2025 |   |   |       2024 |   |
|:---------------------------------------------------------------------------|:--|------------------------------:|:--|:--|-----------:|:--|
| General and administrative                                                 | $ |                     3,120,060 |   | $ |  1,385,981 |   |
| Research and development                                                   |   |                     2,006,214 |   |   |    321,377 |   |
| Total operating expenses                                                   |   |                     5,126,274 |   |   |  1,707,358 |   |
| Loss from operations                                                       |   |                    (5,126,274 | ) |   | (1,707,358 | ) |
| Other income                                                               |   |                               |   |   |            |   |
| Finance income                                                             |   |                        23,866 |   |   |          - |   |
| Total other income                                                         |   |                        23,866 |   |   |          - |   |
| Net loss and comprehensive loss for the year                               | $ |                    (5,102,408 | ) | $ | (1,707,358 | ) |
| Net loss per share attributable to common shareholders - basic and diluted | $ |                         (0.42 | ) | $ |      (0.21 | ) |